Advisory Board

Professor Andrei V. Gudkov

Andrei V. Gudkov, Ph.D., DSc, is Scientific Cofounder of Cleveland Biolabs and has also been its Chief Scientific Officer since June 2003. He serves as Chief Scientific Officer and Founder at Everon Biosciences and at OncoTartis. He cofounded Mega Biotech & Electronics Co, and serves as its Chief Scientific Officer.

Andrei is a Cancer Researcher and appointed Senior Vice President of Research Technology and Innovation; Chair of the Department of Cell Stress Biology, and a member of the senior leadership team for the National Cancer Institute (NCI) Cancer Center Support Grant at the Roswell Park Comprehensive Cancer Center. He served as Senior Vice President of Basic Science at the Roswell Park Cancer Institute.

Andrei serves as the scientific lead for a broad gene- and drug-discovery program, and has pioneered several technologies in these fields. He is responsible for building on the basic and translational research strengths of the Cell Stress Biology program in DNA damage and repair, photodynamic therapy, thermal and hypoxic stress, and immune modulation. As Senior Vice President, he assists the President & CEO in developing and implementing strategic plans for new scientific programs and enhance collaborations in research programs with regional and national academic centers as well as with industry. His interest lies in drug discovery approaches, gene discovery, and molecular targets for cancer treatment.

He has over 25 years of experience in biomedical research and has authored or coauthored more than 200 scientific papers, including papers in Nature, Science, Nature Genetics, and Nature Chemical Biology.

He is an inventor on 38 issued and 41 pending US patents in the cancer area, including the patent for the first p53 inhibitor, pifithrin-alpha. His work is funded by multiple grants from the National Institutes of Health, the Department of Defense, biotech industry, and many research foundations.

More than 25 graduate students and postdocs have been trained in his laboratory, many of whom now hold leadership positions in academia and industry. He is an invited speaker at numerous international congresses.

He serves on the editorial board of several scientific journals, including Oncogene, Cancer Research, Cell Cycle, and Aging. Andrei is the cofounder and co-editor-in-chief of the journal Oncotarget, and Editor-in-Chief of the Oncoscience Journal. He is also the Principal Investigator on a series of NIH-funded programs.

Prior to 1990, he worked with the National Cancer Research Center in Moscow (USSR), where he led a broad research program focused on virology and cancer drug resistance.

In 1990, he re-established his lab at the University of Illinois at Chicago, where he became a tenured faculty member in the Department of Molecular Genetics. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression.

In 2001, Andrei moved his laboratory to the Lerner Research Institute at the Cleveland Clinic Foundation, where he served as Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University.

He is a Scientific Cofounder of Cleveland Biolabs and has been its Chief Scientific Officer and Director since June 2003, which develops new agents discovered in his lab into clinically useful drugs for anticancer and biodefense applications.

In Cleveland, he has continued developing his gene and drug discovery programs, extending them to new cancer areas and drug targets. Many aspects of his work involved collaboration with several industrial partners, including Quark Biotech, PPD Discovery, Clontech, and ChemBridge Corp. Andrei’s work with Quark Biotech resulted in the establishment of a unique long-term relationship between academic and industrial entities that generated millions of dollars of research support for the academic lab and new technologies and drug targets for the industry.

Andrei is the Founder and Chief Scientific Officer of Everon Biosciences which was founded in 2010 to develop anti-aging medicine. They are optimizing several lead compounds, both small molecules and biologics, that have already demonstrated a rejuvenation effect in aging animals, as measured by a lowered mouse Frailty Index (FI).

He also founded Russian Pharmaceutical Company Incuron in 2010 and OncoTartis in 2011, where he serves as Chief Scientific Officer, to develop and translate novel anti-cancer agents discovered in his lab.

Andre also serves as Director of Panacela Labs, Mega Biotech & Electronics Co, and Taiwan Indigena Botanica. He serves as a member of the Scientific Advisory Board at CytoLogic, and as a member of the Scientific Advisory Board at RakFund, a nonprofit organization that supports oncology research in Moscow, Russia.

Andrei earned his doctoral degree in Experimental Oncology at the Cancer Research Center, USSR and his Doctorate of Science (DSc) in Molecular Biology at the Moscow State University, USSR.

His area of general research interest includes drug discovery, gene discovery, and molecular targets for cancer treatment.

His publications include:

Read the news about Andrei’s Preclinical Study on Prostate Cancer.

Watch the interview with Andrei at Aging YouTube Channel talking about his paper p16(Ink4a) and senescence-associated β-galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. Watch Andrei at TEDx Morristown, Can We Stop Aging?

Read about his research at the New York State Stem Cell Science, Department of Health at Wadsworth Center. Read Andrei’s contribution from the book Neuroblastoma — Present and Future in the chapter Small Molecule Drugs and Targeted Therapies for Neuroblastoma.

Read his interview Interventions to extend healthspan and lifespan 2018 which was published in by Elena Milova. Read the outline of his multidisciplinary Research Seminar Series at Cleveland State University.

Visit his LinkedIn profile, main ResearchGate profile and his second profile. View his publications by citation at Google Scholar, his PubFacts profile, ORCID ID page, and Scopus Author ID page. Visit his company’s homepage Everon Biosciences.